Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CAR-T Meeting 2024 | Diminished chronic GvHD symptoms following anti-CD19 CAR T-cell therapy: a case study

Anna Czyz • 17 Feb 2024
CAR-T Meeting 2024
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma CAR-T Tisagenlecleucel

Anna Czyz, MD, PhD, Wroclaw Medical University, Wroclaw, Poland, presents a case study of a patient with diffuse large B-cell lymphoma (DLBCL) who experienced resolution of chronic graft-versus-host disease (GvHD) symptoms following anti-CD19 CAR T-cell infusion. Along with other similar cases reported in the literature, this suggests that anti-CD19 CAR-T therapy may hold the potential for safely and effectively treating GvHD and immune-mediated diseases. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Anna Czyz

1:09
The role of alloSCT in LBCL in the era of CAR-T
Anna Czyz • 17 Feb 2024
0:58
Management strategies for acute and chronic GvHD following alloSCT
Anna Czyz • 17 Feb 2024

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals